Home/ Stocks/ BMRN

BioMarin Pharmaceuticals Inc

BMRN XNAS

$63.81 +0.54 (+0.88%) ▲ 15-min delayed

Open

$64.83

High

$64.92

Low

$62.20

Volume

4.36M

Market Cap

$11.88B

About BioMarin Pharmaceuticals Inc

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 3.2K Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$766.21M	$105.53M	$0.55
FY 2025	$3.22B	$348.90M	$1.82
Q3 2025	$776.13M	$-30,744,000	$-0.16
Q2 2025	$825.41M	$240.53M	$1.25

Related Market News

No specific coverage for BMRN yet. Check out our latest market news or earnings calendar.

Get BMRN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BioMarin Pharmaceuticals Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.